Recent advances in monoclonal antibody therapy of cancer indicate that this therapeutic strategy is beginning to realize its potential after twenty years of intensive preclinical and clinical trial research. The central hypothesis of our work continues to be that multifunctional antibody-based proteins targeting tumors and host effector cells can stimulate host-protective anti-tumor immune responses. This hypothesis has been addressed through the construction and testing of bispecific antibodies (BsAb) that efficiently promote targeted cellular cytotoxicity. In the current funding period, we have shown that whole IgG bispecific antibodies targeting tumor antigens and human effector cell trigger molecules cause systemic toxicities that restrict antibody doses and efficacy. The potential of targeted cellular therapy is also restricted by the limited availability of potentially inflammatory effector cells in the tumor microenvironment. Using human phage- displayed single-chain Fv fragment-based BsAb as templates, we will systematically modify these structures to develop improved reagents and strategies to promote targeted tumor inflammation. The first specific aim is to optimize the structure of bispecific antibodies (BsAb) targeting HER2/neu and human Fc-gamma-RIII for tumor targeting and cytotoxicity promotion. We hypothesize that increasing the size and span of this BsAb will enhance its tumor- specific cytotoxicity properties. C6B1D2-Y3, a single-chain Fv (scFv) dimeric BsAb with high affinity for HER2/neu and lower affinity for human Fc-gamma-RIII will serve as the template for these efforts. The second specific aim is to introduce leukocyte chemotactic or proliferative moieties into a structurally optimized antibody or BsAb format to promote leukocyte infiltration into tumor sites. We hypothesize that this will enhance the accumulation of potentially cytolytic effector cells at tumor sites, facilitating BsAb-directed therapy. The third specific aim is to develop antibody-targeting strategies to assemble the bacterial superantigens, staphylococcal enterotoxin A or B, specifically on tumor cells to promote in situ antibody-targeted superantigen- mediated cytotoxicity. We will test the hypothesis that antibody- directed assembly of intact superantigens at tumor sites from biologically inactive fragments will facilitate tumor-specific T cell activation. If validated, this will lead to clinical trials of antibody-directed superantigen assembly on tumor cell surfaces and will demonstrate the feasibility of this general strategy for tumor-specific immunomodulation. The successful achievement of these aims will identify new therapeutic reagents and strategies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA050633-11
Application #
6172554
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Yovandich, Jason L
Project Start
1989-06-01
Project End
2003-04-30
Budget Start
2000-05-05
Budget End
2001-04-30
Support Year
11
Fiscal Year
2000
Total Cost
$402,025
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Smith, Jill P; Wang, Shangzi; Nadella, Sandeep et al. (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195-207
Aldeghaither, Dalal S; Zahavi, David J; Murray, Joseph C et al. (2018) A Mechanism of Resistance to Antibody-Targeted Immune Attack. Cancer Immunol Res :
Shuptrine, Casey W; Ajina, Reham; Fertig, Elana J et al. (2017) An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection. Cancer Immunol Immunother 66:1529-1544
Berens, E B; Sharif, G M; Schmidt, M O et al. (2017) Keratin-associated protein 5-5 controls cytoskeletal function and cancer cell vascular invasion. Oncogene 36:593-605
Varghese, Rency S; Zuo, Yiming; Zhao, Yi et al. (2017) Protein network construction using reverse phase protein array data. Methods 124:89-99
Zhang, Yong-Wei; Nasto, Rochelle E; Jablonski, Sandra A et al. (2017) RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio Protoc 7:
Murakami, S; Shahbazian, D; Surana, R et al. (2017) Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. Oncogene 36:1232-1244
Gibney, Geoffrey T; Weiner, Louis M; Atkins, Michael B (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542-e551
Zhang, Y-W; Nasto, R E; Varghese, R et al. (2016) Acquisition of estrogen independence induces TOB1-related mechanisms supporting breast cancer cell proliferation. Oncogene 35:1643-56
Redman, J M; Hill, E M; AlDeghaither, D et al. (2015) Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 67:28-45

Showing the most recent 10 out of 58 publications